Home › Trial NCT05341349
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
- Trial IDNCT05341349
- StatusTerminated
- PhasePhase 1
- Study typeInterventional
- SponsorEmory University
- Enrollment1
- Start date2022-10-13
- ConditionsClinical Stage IV Cutaneous Melanoma AJCC v8 · Melanoma of Unknown Primary · Metastatic Malignant Neoplasm in the Brain · Metastatic Melanoma · Metastatic Mucosal Melanoma · Metastatic Ocular Melanoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.